{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T08:29:12Z","timestamp":1772612952549,"version":"3.50.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oarsijournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoarthritis and Cartilage"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.joca.2015.12.011","type":"journal-article","created":{"date-parts":[[2015,12,30]],"date-time":"2015-12-30T21:45:12Z","timestamp":1451511912000},"page":"776-785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration"],"prefix":"10.1016","volume":"24","author":[{"given":"E.","family":"Losina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Michl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.E.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3197-752X","authenticated-orcid":false,"given":"D.J.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Yelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.D.","family":"Paltiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.N.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.joca.2015.12.011_bib1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II","volume":"58","author":"Lawrence","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2015.12.011_bib2","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Bhala","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.joca.2015.12.011_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejpain.2006.02.013","article-title":"Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials","volume":"11","author":"Bjordal","year":"2007","journal-title":"Eur J Pain"},{"key":"10.1016\/j.joca.2015.12.011_bib4","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/bmj.38273.626655.63","article-title":"Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials","volume":"329","author":"Bjordal","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.joca.2015.12.011_bib5","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/archinte.165.9.978","article-title":"Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study","volume":"165","author":"Johnsen","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.joca.2015.12.011_bib6","first-page":"708","article-title":"Nonsteroidal antiinflammatory drug discontinuation in patients with osteoarthritis","volume":"22","author":"Scholes","year":"1995","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.joca.2015.12.011_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00045391-200007020-00004","article-title":"Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics","volume":"7","author":"Whelton","year":"2000","journal-title":"Am J Ther"},{"key":"10.1016\/j.joca.2015.12.011_bib8","doi-asserted-by":"crossref","first-page":"R1046","DOI":"10.1186\/ar1782","article-title":"Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids","volume":"7","author":"Moore","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.joca.2015.12.011_bib9","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1001\/archinternmed.2010.391","article-title":"The comparative safety of analgesics in older adults with arthritis","volume":"170","author":"Solomon","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.joca.2015.12.011_bib10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2106\/JBJS.L.00206","article-title":"Estimating the burden of total knee replacement in the United States","volume":"95","author":"Weinstein","year":"2013","journal-title":"J\u00a0Bone Joint Surg Am"},{"key":"10.1016\/j.joca.2015.12.011_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/acr.22412","article-title":"Lifetime medical costs of knee osteoarthritis management in the United States: impact of extending indications for total knee arthroplasty","volume":"67","author":"Losina","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.joca.2015.12.011_bib12","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/S0885-3924(02)00411-6","article-title":"The impact of pain management on quality of life","volume":"24","author":"Katz","year":"2002","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.joca.2015.12.011_bib13","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nm0895-774","article-title":"The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule","volume":"1","author":"McMahon","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.joca.2015.12.011_bib14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.tips.2005.12.001","article-title":"Novel class of pain drugs based on antagonism of NGF","volume":"27","author":"Hefti","year":"2006","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.joca.2015.12.011_bib15","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1136\/annrheumdis-2012-203164","article-title":"Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial","volume":"73","author":"Balanescu","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2015.12.011_bib16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd3732","article-title":"Anti-NGF painkillers back on track?","volume":"11","author":"Holmes","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.joca.2015.12.011_bib17","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa0901510","article-title":"Tanezumab for the treatment of pain from\u00a0osteoarthritis of the knee","volume":"363","author":"Lane","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.joca.2015.12.011_bib18","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/annrheumdis-2013-204905","article-title":"Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain","volume":"74","author":"Schnitzer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2015.12.011_bib19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.joca.2011.01.009","article-title":"Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain","volume":"19","author":"Schnitzer","year":"2011","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2015.12.011_bib20","first-page":"790","article-title":"Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial","volume":"13","author":"Brown","year":"2012","journal-title":"J\u00a0Pain"},{"key":"10.1016\/j.joca.2015.12.011_bib21","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.joca.2011.09.006","article-title":"Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study","volume":"19","author":"Nagashima","year":"2011","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2015.12.011_bib22","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.pain.2013.04.035","article-title":"A\u00a0phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee","volume":"154","author":"Spierings","year":"2013","journal-title":"Pain"},{"key":"10.1016\/j.joca.2015.12.011_bib23","first-page":"313","article-title":"Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis","volume":"17","author":"Wong","year":"2011","journal-title":"J\u00a0Manag Care Pharm"},{"key":"10.1016\/j.joca.2015.12.011_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.23177","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I","volume":"58","author":"Helmick","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2015.12.011_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.joca.2015.02.655","article-title":"Comparative efficacy of oral non-steroidal anti-inflammatory drugs and opioids for osteoarthritis: systematic review and meta-analysis","author":"Smith","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2015.12.011_bib26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MLR.0b013e31815c31a7","article-title":"What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?","volume":"46","author":"Braithwaite","year":"2008","journal-title":"Med Care"},{"key":"10.1016\/j.joca.2015.12.011_bib27","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/archinte.163.14.1637","article-title":"What is the price of life and why doesn't it increase at the rate of inflation?","volume":"163","author":"Ubel","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.joca.2015.12.011_bib28","article-title":"The willingness to pay for a quality adjusted life year: a review of the empirical literature","author":"Ryen","year":"2014","journal-title":"Health Econ"},{"key":"10.1016\/j.joca.2015.12.011_bib29","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jama.1996.03540160061034","article-title":"Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine","volume":"276","author":"Siegel","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.joca.2015.12.011_bib30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2106\/JBJS.J.01958","article-title":"The dramatic increase in total knee replacement utilization rates in the United States cannot be fully explained by growth in population size and the obesity epidemic","volume":"94","author":"Losina","year":"2012","journal-title":"J\u00a0Bone Joint Surg Am"},{"key":"10.1016\/j.joca.2015.12.011_bib31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.joca.2010.10.009","article-title":"Forecasting the burden of advanced knee osteoarthritis over a 10-year period in a cohort of 60\u201364 year-old US adults","volume":"19","author":"Holt","year":"2011","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2015.12.011_bib32","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/archinternmed.2009.136","article-title":"Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume","volume":"169","author":"Losina","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.joca.2015.12.011_bib33","series-title":"National Health Interview Survey (NHIS). Centers for Disease Control and Prevention (CDC), and National Center for Health Statistics (NCHS), U.S. Department of Health and Human Services (DHHS)","year":"2010"},{"key":"10.1016\/j.joca.2015.12.011_bib34","series-title":"2009\u20132012 National Health and Nutrition Examinations Survey (NHANES) Data","author":"Centers for Disease Control and Prevention (CDC)","year":"2011"},{"key":"10.1016\/j.joca.2015.12.011_bib35","series-title":"National Vital Statistics System (NVSS) (Accessed from Health Data Interactive).Centers for Disease Control and Prevention (CDC), and National Center for Health Statistics (NCHS), U.S. Department of Health and Human Services (DHHS)","year":"2010"},{"key":"10.1016\/j.joca.2015.12.011_bib36","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1000367","article-title":"Body-mass index and mortality among 1.46 million white adults","volume":"363","author":"Berrington de Gonzalez","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.joca.2015.12.011_bib37","series-title":"United States Life Tables: Centers for Disease Control, US Department of Health and Human Services","year":"2010"},{"key":"10.1016\/j.joca.2015.12.011_bib38","first-page":"172","article-title":"Prevalence of knee symptoms and radiographic and symptomatic knee osteoarthritis in African Americans and Caucasians: the Johnston County Osteoarthritis Project","volume":"34","author":"Jordan","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.joca.2015.12.011_bib39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2474-9-55","article-title":"Cutpoints for mild, moderate and severe pain in patients with osteoarthritis of the hip or knee ready for joint replacement surgery","volume":"9","author":"Kapstad","year":"2008","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.joca.2015.12.011_bib40","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s11999-009-1046-9","article-title":"Comparing patient outcomes after THA and TKA: is there a difference?","volume":"468","author":"Bourne","year":"2010","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.joca.2015.12.011_bib41","first-page":"131","article-title":"Minimal clinically important rehabilitation effects in patients with osteoarthritis of the lower extremities","volume":"29","author":"Angst","year":"2002","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.joca.2015.12.011_bib42","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard.2004.022905","article-title":"Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement","volume":"64","author":"Tubach","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2015.12.011_bib43","series-title":"Osteoarthritis Initiative (OAI)","year":"2013"},{"key":"10.1016\/j.joca.2015.12.011_bib44","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/01.mlr.0000135827.18610.0d","article-title":"The estimation of a preference-based measure of health from the SF-12","volume":"42","author":"Brazier","year":"2004","journal-title":"Med Care"},{"key":"10.1016\/j.joca.2015.12.011_bib45","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00005650-200103000-00002","article-title":"Determining the need for hip and knee arthroplasty: the role of clinical severity and patients' preferences","volume":"39","author":"Hawker","year":"2001","journal-title":"Med Care"},{"key":"10.1016\/j.joca.2015.12.011_bib46","series-title":"Centers for Disease Control and Prevention. National Center for Health Statistics. National Health Interview Survey (NHIS)","year":"2012"},{"key":"10.1016\/j.joca.2015.12.011_bib47","first-page":"119","article-title":"Risk adjustment of Medicare capitation payments using the CMS-HCC model","volume":"25","author":"Pope","year":"2004","journal-title":"Health Care Financ Rev"},{"key":"10.1016\/j.joca.2015.12.011_bib48","series-title":"Red Book: Pharmacy's Fundamental Reference","year":"2012"},{"key":"10.1016\/j.joca.2015.12.011_bib49","series-title":"Medicare Current Beneficiary Survey","year":"2009"},{"key":"10.1016\/j.joca.2015.12.011_bib50","series-title":"Tanezumab Arthritis Advisory Committee Briefing Document","year":"2012"},{"key":"10.1016\/j.joca.2015.12.011_bib51","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1136\/ard.2005.038349","article-title":"A\u00a0long-term, open-label trial of the\u00a0safety and efficacy of etanercept (Enbrel) in patients with\u00a0rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs","volume":"65","author":"Klareskog","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2015.12.011_bib52","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1185\/030079907X242575","article-title":"Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK","volume":"23","author":"Jansen","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.joca.2015.12.011_bib53","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.1524-4733.2003.00215.x","article-title":"The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis","volume":"6","author":"Kamath","year":"2003","journal-title":"Value Health"},{"key":"10.1016\/j.joca.2015.12.011_bib54","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joca.2014.01.005","article-title":"Pharmacologic regimens for knee osteoarthritis prevention: can they be cost-effective?","volume":"22","author":"Losina","year":"2014","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2015.12.011_bib55","article-title":"Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities","author":"Katz","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"issue":"Suppl 1","key":"10.1016\/j.joca.2015.12.011_bib56","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.joca.2014.10.005","article-title":"Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies","volume":"23","author":"Hochberg","year":"2015","journal-title":"Osteoarthritis Cartilage"},{"issue":"Suppl 2","key":"10.1016\/j.joca.2015.12.011_bib57","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2106\/JBJS.J.00807","article-title":"A\u00a0prospective study of 80,000 total joint and 5000 anterior cruciate ligament reconstruction procedures in a community-based registry in the United States","volume":"92","author":"Paxton","year":"2010","journal-title":"J\u00a0Bone Joint Surg Am"},{"key":"10.1016\/j.joca.2015.12.011_bib58","series-title":"Medicare Fee Schedules","year":"2014"},{"key":"10.1016\/j.joca.2015.12.011_bib59","series-title":"Medicare Hospital Outpatient Prospective Payment System","year":"2014"},{"key":"10.1016\/j.joca.2015.12.011_bib60","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.pain.2014.06.004","article-title":"Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain","volume":"155","author":"Gimbel","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.joca.2015.12.011_bib61","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/pme.12677","article-title":"Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain","volume":"16","author":"Bramson","year":"2015","journal-title":"Pain Med"},{"key":"10.1016\/j.joca.2015.12.011_bib62","series-title":"Red Book Online\u00ae","year":"2015"},{"key":"10.1016\/j.joca.2015.12.011_bib63","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.joca.2015.12.011_bib64","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.joca.2015.12.011_bib65","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.joca.2015.12.011_bib66","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.joca.2015.12.011_bib67","first-page":"1196","article-title":"All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database","volume":"30","author":"Watson","year":"2003","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.joca.2015.12.011_bib68","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/annrheumdis-2013-204021","article-title":"Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFalpha inhibitors and rituximab","volume":"74","author":"Listing","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2015.12.011_bib69","doi-asserted-by":"crossref","first-page":"d1165","DOI":"10.1136\/bmj.d1165","article-title":"All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study","volume":"342","author":"Nuesch","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.joca.2015.12.011_bib70","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/art.22333","article-title":"Association of hospital and surgeon procedure volume with patient-centered outcomes of total knee replacement in a population-based cohort of patients age 65 years and older","volume":"56","author":"Katz","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2015.12.011_bib71","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1302\/0301-620X.95B1.29835","article-title":"Predicting the cost-effectiveness of total hip and knee replacement: a health economic analysis","volume":"95-B","author":"Jenkins","year":"2013","journal-title":"Bone Joint J"},{"key":"10.1016\/j.joca.2015.12.011_bib72","series-title":"Healthcare Cost and Utilization Project (HCUP). Nationwide Inpatient Sample (NIS). Agency for Healthcare Research and Quality","year":"2012"},{"key":"10.1016\/j.joca.2015.12.011_bib73","series-title":"Consumer Price Index (CPI)","year":"2014"}],"container-title":["Osteoarthritis and Cartilage"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S106345841501434X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S106345841501434X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:40:42Z","timestamp":1761018042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S106345841501434X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S106345841501434X"],"URL":"https:\/\/doi.org\/10.1016\/j.joca.2015.12.011","relation":{},"ISSN":["1063-4584"],"issn-type":[{"value":"1063-4584","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration","name":"articletitle","label":"Article Title"},{"value":"Osteoarthritis and Cartilage","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joca.2015.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Osteoarthritis Research Society International. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}